Japan's biggest drug maker is making eyes at the US market as its patents get closer to their expiration dates. Takeda Pharmaceutical said it would pay $100 million to be Alnylam Pharmaceuticals' strategic partner in RNAi therapeutics, says the Wall Street Journal. Under this five-year agreement, Takeda will have the right to first negotiation to develop Alnylam products for the Asian market and Alnylam would have the option to develop Takeda's programs in the US.
Batting Eyelashes and All
May 27, 2008